Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients.
Mandó P, Rizzo M, Roberti MP, Juliá EP, Pampena MB, Pérez de la Puente C, Loza CM, Ponce C, Nadal J, Coló FA, Mordoh J, Levy EM. Mandó P, et al. Among authors: mordoh j. Onco Targets Ther. 2018 May 17;11:2901-2910. doi: 10.2147/OTT.S160911. eCollection 2018. Onco Targets Ther. 2018. PMID: 29844687 Free PMC article.
IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.
Roberti MP, Rocca YS, Amat M, Pampena MB, Loza J, Coló F, Fabiano V, Loza CM, Arriaga JM, Bianchini M, Barrio MM, Bravo AI, Domenichini E, Chacón R, Mordoh J, Levy EM. Roberti MP, et al. Among authors: mordoh j. Breast Cancer Res Treat. 2012 Dec;136(3):659-71. doi: 10.1007/s10549-012-2287-y. Epub 2012 Oct 14. Breast Cancer Res Treat. 2012. PMID: 23065032
Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.
Roberti MP, Juliá EP, Rocca YS, Amat M, Bravo AI, Loza J, Coló F, Loza CM, Fabiano V, Maino M, Podhorzer A, Fainboim L, Barrio MM, Mordoh J, Levy EM. Roberti MP, et al. Among authors: mordoh j. Eur J Immunol. 2015 May;45(5):1560-9. doi: 10.1002/eji.201445353. Epub 2015 Apr 7. Eur J Immunol. 2015. PMID: 25726929 Free article.
Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients.
Juliá EP, Mandó P, Rizzo MM, Cueto GR, Tsou F, Luca R, Pupareli C, Bravo AI, Astorino W, Mordoh J, Martín C, Levy EM. Juliá EP, et al. Among authors: mordoh j. Cancer Immunol Immunother. 2019 Oct;68(10):1585-1596. doi: 10.1007/s00262-019-02391-z. Epub 2019 Sep 12. Cancer Immunol Immunother. 2019. PMID: 31515670 Free PMC article.
146 results